Moleculin Biotech, Inc. 8-K

What Happened Moleculin Biotech, Inc. (MBRX) filed a Form 8‑K (Item 7.01) on May 29, 2026 to disclose a press release issued the same day announcing new data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The release reports results that further reinforce the differentiated cardiac safety profile of the company’s lead drug candidate, Annamycin (also called L‑Annamycin or naxtarubicin). The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: May 29, 2026 (Form 8‑K, Item 7.01 — Regulation FD Disclosure).
• Event: New Annamycin safety data presented at the 2026 ASCO Annual Meeting.
• Drug: Annamycin (L‑Annamycin / naxtarubicin) — lead candidate for Moleculin.
• Attachment: Press release dated May 29, 2026 included as Exhibit 99.1 to the 8‑K.

Why It Matters Cardiac safety is a key concern for oncology drugs, especially anthracycline-related compounds. Reinforced safety data reported at a major scientific meeting (ASCO) can be material information for investors because it may affect the perceived clinical and regulatory risk profile of Annamycin and investor confidence in the program. The company complied with Regulation FD by publicly disclosing the information via the 8‑K and attached press release.